Combination chemotherapy in accelerated phase of chronic granulocytic leukemia.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000740:Anemia; D001792:Blood Platelets; D001803:Blood Transfusion; D001806:Blood Urea Nitrogen; D001854:Bone Marrow Cells; D001856:Bone Marrow Examination; D002869:Chromosome Aberrations; D003587:Cytomegalovirus; D005260:Female; D005334:Fever; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D007565:Jaundice / Q000139:chemically induced; D007951:Leukemia, Myeloid / Q000150:complications / Q000188:drug therapy*; D007958:Leukocyte Count; D007962:Leukocytes / Q000166:cytology; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D015122:Mercaptopurine / Q000009:adverse effects / Q000627:therapeutic use*; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D009617:Nocardia Infections; D011014:Pneumonia; D011241:Prednisone / Q000009:adverse effects / Q000627:therapeutic use*; D011512:Proteus Infections; D011552:Pseudomonas Infections; D018805:Sepsis; D013921:Thrombocytopenia / Q000139:chemically induced; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use*
D014750:Vincristine; D015122:Mercaptopurine; D011241:Prednisone; D008727:Methotrexate